The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

(Alliance News) - Pharmaceutical firm GSK PLC and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or ...

GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.

This European review of the prefilled syringe follows GSK's receipt of approval from the US Food & Drug Administration on January 8. GSK is also investigating submission of the new presentation to ...

London stocks were set to fall at the open on Monday following a mostly weaker Asian session. The FTSE 100 was called to open ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer preve ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...